Director, Product Quality and Analytical Methods, Digital and Innovation, US Pharmacopeia, Rockville, MD.
J Manag Care Spec Pharm. 2021 Apr;27(4):533-535. doi: 10.18553/jmcp.2021.27.4.533.
No funding supported the writing of this commentary. The author is employed by US Pharmacopeia. This article was requested by JMCP as a response to the companion Viewpoints article "Decision Makers Need an Approach to Determine Digital Therapeutic Product Quality, Access, and Appropriate Use" by Parcher and Coder (see page 536). Digital Therapeutics Alliance, which is mentioned in this article, is a member of the USP Convention.
本评论文章的撰写未获得任何资金支持。作者为美国药典（USP）员工。本文由《JMCP》要求撰写，以回应 Parcher 和 Coder 的观点文章“决策者需要一种方法来确定数字治疗产品的质量、可及性和合理使用”（见第 536 页）。本文中提到的数字治疗联盟（Digital Therapeutics Alliance）是 USP 大会的成员。
